微RNA作为氨酸激酶抑制剂抗癌的敏感剂:小分子合作伙伴关系
Alma D Campos-Parra1, David Sánchez-Marín2, Víctor Acevedo-Sánchez1
1Instituto de Salud Pública, Universidad Veracruzana (UV), Xalapa 91190, Mexico.
Pharmaceuticals (Basel, Switzerland)
|April 26, 2025
概括
微RNA (miRNA) 可以增强癌症患者对氨酸激酶抑制剂 (TKI) 的敏感性. 本综述提出了一项工作流程,以选择最佳miRNA候选者,克服TKI-miRNA组合疗法的挑战.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 氨酸激酶抑制剂 (TKIs) 改善了癌症患者的存活率,但却面临抗药性.
- 微RNAs (miRNAs) 显示出克服TKI耐药性的潜力.
- 选择最佳的miRNA用于临床使用是一个重大的挑战,因为它们的广泛向.
研究的目的:
- 审查miRNAs如何在各种癌症中增强TKI敏感性.
- 突出TKI-miRNA组合疗法的挑战和局限性.
- 提出一个工作流程来选择适合的miRNA候选人进行临床试验.
主要方法:
- 关于miRNA介导的TKI敏感性的文献综述.
- 分析miRNA-TKI治疗策略中的挑战.
- 关于为miRNA候选人选择提供生物信息学指导的工作流程的建议.
主要成果:
- miRNAs可以在不同类型的癌症中重新使癌细胞对TKI敏感.
- 选择特定的miRNAs用于有效的组合疗法存在重大挑战.
- 生物信息学工具可以帮助识别最佳miRNA候选者.
结论:
- 需要一个系统的方法来选择miRNAs用于TKI组合疗法.
- 拟议的工作流旨在促进开发成功的TKI-miRNA疗法.
- 此次临床翻译提案支持进一步的研究.
更多相关视频
相关概念视频
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Abnormal Proliferation
4.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Receptor Tyrosine Kinases
11.7K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
11.7K


